Azer-cel trial shows early signals in progressive MS

Azer-cel trial results announced by TG Therapeutics on October 23, 2026, showed preliminary safety and disability signals in patients with progressive multiple sclerosis. The company reported no severe toxicities or dose-limiting adverse events, alongside signs of stable or improved disability scores. The Phase 1 findings remain early and do not establish the investigational therapy’s effectiveness.

Key Takeaways

• TG Therapeutics reported no severe toxicities or dose-limiting adverse events in the preliminary findings.
• Disability, walking and cognitive measures showed early signals, but detailed response rates were not provided in the supplied information.
• Azer-cel uses donor-derived T cells, distinguishing it from CAR T-cell treatments manufactured from each patient’s own cells.

Table of Contents

• Azer-cel trial findings center on safety and disability
• A donor-derived approach targets CD19
• An early pipeline result, not a new approved treatment
• Conclusion

Azer-cel trial findings center on safety and disability

Participants had experienced disease progression despite previous disease-modifying therapies. TG Therapeutics presented the preliminary findings at MSToronto2026.

The company said a high proportion of participants maintained or improved their Expanded Disability Status Scale scores at 90 and 180 days. It also reported benefits in walking ability and cognitive processing speed, together with substantial B-cell depletion.

Those observations support further investigation, rather than a conclusion that the treatment reverses progressive MS. The supplied information does not give the exact proportions with improved disability scores, the number assessed at each follow-up point or the magnitude of the walking and cognitive changes.

A donor-derived approach targets CD19

Azercabtagene zapreleucel, shortened to azer-cel, is an investigational CD19-directed CAR T-cell therapy. TG Therapeutics’ azer-cel development overview explains that it uses healthy donor T cells rather than cells collected individually from each patient.

The donor cells are modified to express a CD19-directed receptor while minimizing the risk of graft-versus-host disease. The company describes the allogeneic, or off-the-shelf, approach as designed to support rapid availability and scalable manufacturing; those are development objectives, not outcomes established by these preliminary clinical findings.

The reported B-cell depletion is consistent with the therapy’s intended biological action. That finding is distinct from demonstrating a durable improvement in patients’ disability.

An early pipeline result, not a new approved treatment

TG Therapeutics already markets BRIUMVI, an FDA-approved anti-CD20 antibody for relapsing forms of MS. Azer-cel targets CD19 and is being investigated in progressive MS, so the latest findings concern a separate pipeline program rather than an expanded approval for BRIUMVI.

For the company’s development program, the key distinction is between encouraging early observations and evidence sufficient to establish lasting clinical benefit. The Phase 1 evaluation remains focused on safety, tolerability and preliminary clinical activity.

Conclusion

The next focus for the ongoing azer-cel trial is whether further follow-up supports the initial safety findings and shows sustained clinical activity. The preliminary results do not yet establish a durable treatment benefit in progressive MS.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.